ClinicalTrials.gg
CompletedNCT05593861Updated Oct 25, 2022

Assessment of Enhanced Recovery After Surgery Implementation at Pediatric Surgery Practices in Mainland China

An observational study in ERAS, sponsored by Weibing Tang. Completed at 1 site in China. Per ClinicalTrials.gov, last updated 2022-10-25.

Sponsored by Weibing Tang · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Cross-sectional
Enrollment
66
Sex
All
01

Study summary

Enhanced recovery after surgery (ERAS) is a new mode to optimize perioperative management, the core of which is to reduce perioperative physiological and psychological trauma and stress damage, and accelerate postoperative rehabilitation. ERAS has been gradually introduced in pediatric surgery in recent years, however, there are limited reports on its overall implementation. We aimed to determine the popularity of ERAS among pediatric populations in mainland China.

Read the detailed description

The application of ERAS in children with congenital biliary dilatation (CBD) was investigated. A total of 31 province-level administrative regions in mainland China were involved and each of them had at least one participating center. A questionnaire was designed to assess the baseline adherence of 17 recovery elements and chief pediatric surgeons at each center were invited to complete.

02

Conditions studied

  • ERAS
03

In context

Lead sponsor

Weibing Tang is the lead sponsor of 6 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

chief pediatric surgeons at each center

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • chief pediatric surgeons at each center

Exclusion criteria

Exclusion Criteria:

  • Incomplete questionnaire
05

Study design

Observational model
Other
Time perspective
Cross-sectional
Enrollment
66 participants (actual)
Patient registry
No

Groups and cohorts

  • This investigation was conducted on chief surgeons at each center.

    This investigation was conducted on chief surgeons at each center.

06

What researchers measure

Primary outcomes

  1. Element adherence

    Adherence to an element was determined if the frequency of practice reached specific thresholds as defined.

    Time frame: immediately after all the questionnaires are collected

Secondary outcomes

  1. Factors associated with baseline ERAS utilization

    Factors associated with baseline ERAS utilization

    Time frame: immediately after all the questionnaires are collected

Other outcomes

  1. Barriers to implementation

    Barriers to implementation

    Time frame: immediately after all the questionnaires are collected

  2. Outcomes of concern

    Outcomes of concern

    Time frame: immediately after all the questionnaires are collected

07

Study locations

1 site
  • NJMU
    Nanjing, Jiangsu, China
08

References and documents

Publications

  • Vacek J, Davis T, Many BT, Close S, Blake S, Hu YY, Holl JL, Johnson J, Strople J, Raval MV. A baseline assessment of enhanced recovery protocol implementation at pediatric surgery practices performing inflammatory bowel disease operations. J Pediatr Surg. 2020 Oct;55(10):1996-2006. doi: 10.1016/j.jpedsurg.2020.06.021. Epub 2020 Jun 27. PubMed 32713714 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2021 to primary completion in Jul 2022, 12 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 25, 2022
First posted
Oct 25, 2022
StartActual
Jul 1, 2021
Primary completionActual
Jul 1, 2022
CompletionActual
Jul 21, 2022
Last update
Oct 25, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 25, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05593861
Lead sponsor
Weibing Tang
Responsible party
Weibing Tang (Doctor, Nanjing Children's Hospital) — Sponsor-investigator
First posted
Oct 25, 2022
Start date
Jul 1, 2021
Primary completion
Jul 1, 2022
Completion
Jul 21, 2022
Last update
Oct 25, 2022

Study contacts

Hua Xie, M.M.
principal investigator · Department of pediatric Surgery, Children's Hospital of Nanjing Medical University, Nanjing, China.

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion